The FDA has approved tebentafusp-tebn (Kimmtrak – Immunocore), a first-in-class bispecific gp100 peptide-HLA-directed CD3 T-cell engager, for treatment of HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults.

The alkylating agent melphalan (Hepzato – Delcath) has been approved by the FDA for treatment of uveal melanoma in adults with unresectable hepatic metastases that affects <50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Melphalan is available in a kit (Hepzato Kit) that contains a hepatic delivery system for infusion into the hepatic artery. The drug has been available for years in a tablet formulation for treatment of multiple myeloma and palliative treatment of nonresectable epithelial ovarian cancer and in an IV solution for treatment of multiple myeloma.